Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, ...

Data presented at ASH suggested that CDK4/6 inhibitors given with chemo for Rb-deficient tumors could mitigate the risk of secondary myeloid neoplasms.

Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean ...

The efficacy of exa-cel was the same in patients ages 5 to 11 years compared with those ages 12 to 17 years, he noted, adding that exa-cel "has the potential to provide a one-time functional cure for ...

For more than 20 years, women entering menopause were told to be afraid of hormone replacement therapy. Headlines warned of ...

Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...

Tumor treating fields are emerging as a promising option for treating a range of cancer types. Here’s a look at the evidence ...

The results are a major blow for a company that had been one of the leaders in the RNA editing field. Korro went public in 2023 via a reverse merger with Frequency Therapeutics that left it with about ...

Our AI models have generated three distinct trading strategies tailored to different risk profiles and holding periods. Each strategy incorporates sophisticated risk management parameters designed to ...